Replies to post #724264 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Gary,

Here is the part from the description of the combo trial. I really think that we need to reevaluate some of our understandings about DCVax-L. The anti-tumor response from the combo trial has the intensity beyond imagination. With all the precision surgery development such as CLPT, all the patients need is enough tissue to make the vaccine. At most, they can simply get the tumor removed and spare the surrounding tissues which have both normal cells and cancer cells. T cells will wipe out all the cancer cells left.

Must be undergoing surgery that is clinically indicated, and eligible for resection with the expectation that the surgeon is able to resect at least 2 gram of tumor for lysate and research with low risk of inducing neurological injury

[Horseb4CarT]

I remember some earlier information, maybe from Dr Liau or Dr Bosch, that dcvax monotherapy (added to SOC) response depended on remaining tumor load, thus maximum removal of tumor was thought to be the goal of the surgery.

I don’t know if current knowledge has modified the thinking.